To test the potential use of the iSUF platform in screening biomarkers for BC, we processed 0.5 mL of serum from 10 metastatic BC patients and quantified the expression levels of HER2, CD24, and miR21 on patient isolated EVs49–51. This evidence concerns the gene ERBB2 and breast cancer.